AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17932248
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate therapy
Trial: 7835803
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus a platinum compound
Trial: 3323072
Drug: terbutaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline (10 mg/day) and metoprolol (200 mg/day)
Trial: 3323072
Drug: metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (200 mg/day) alone
Trial: 3323072
Drug: terbutaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline (10 mg/day) alone
Trial: 23910665
Drug: Ipragliflozin 600
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 600 mg/d for 7 days
Trial: 23910665
Drug: Ipragliflozin 100
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 100 mg/d for 7 days
Trial: 21270330
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy targeting normoglycemia
Trial: 16458451
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose levamisole (LMS)
Trial: 11478456
Drug: Ivermectin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (100 ug/kg body weight, 2 doses, 3 months apart)
Trial: 3045069
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy with vidarabine sodium phosphate in an aqueous gel
Trial: 9703563
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg papaverine
Trial: 8580278
Drug: 5-ASA enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA enema (mesalazine 1 g/100 mL)
Trial: 2293938
Drug: One-step application
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step application of a water-insoluble iodophor-in-alcohol solution
Trial: 33455
Drug: Thiopentone (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (3.5 mg/kg)
Trial: 33455
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (1 mg/kg)
Trial: 27753282
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation 2
Trial: 27753282
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation 3
Trial: 26083828
Drug: Aleph inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleph inactivated split influenza vaccine
Trial: 20043525
Drug: Intramuscular syntometrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular syntometrine (syntocinon 10 IU + ergometrine 0.5 mg)
Trial: 17374344
Drug: Boiled extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled extract of Carum copticum (0.125 ml/kg and 0.25 ml/kg)
Trial: 17374344
Drug: Theophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (6 mg/kg)
Trial: 15596918
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens in phase III clinical trials
Trial: 9150013
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with nitrous/narcotic and inhalation anesthesia for maintenance
Trial: 2949876
Drug: qi‐regulating; blood‐activating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qi‐regulating; blood‐activating and wind‐dispelling Chinese medicine (A group, 100 cases)
Trial: 2949876
Drug: cortical hormone
RxNorm normalized name: Adrenal cortical hormone-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cortical hormone (B group, 51 cases)
Trial: 2949876
Drug: yin‐nourishing; blood‐activating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yin‐nourishing; blood‐activating and wind‐dispelling Chinese medicine (C group, 53 cases)
Trial: 29440005
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg·d‐1)
Trial: 29440005
Drug: Bumetanide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (1 mg·d‐1)
Trial: 29440005
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Dapagliflozin and Bumetanide)
Trial: 15882209
Drug: Binary system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binary system containing block copolymers as solution rinse
Trial: 15882209
Drug: Ternary system
RxNorm normalized name: Prednisolone tertiary butylacetate
DrugBank: Prednisolone tebutate (DB14632)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ternary system containing block copolymers and polypeptide as solution rinse
Trial: 7775634
Drug: Oxandrolone 2.5
RxNorm normalized name: oxandrolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 2.5 mg daily
Trial: 7775634
Drug: Testosterone 50
RxNorm normalized name: testosterone 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 50 mg monthly IM injections
Trial: 7775634
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (Oxandrolone and Testosterone)
Trial: 2270749
Drug: Essential fatty
RxNorm normalized name: essential fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential fatty acid therapy (8 x 500 mg capsules per day for 3 months)
Trial: 2270749
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 x 500 mg capsules per day for 3 months)
Trial: 10709150
Drug: oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral verapamil
Trial: 9166816
Drug: Hyskon (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyskon (250 ml 32% dextran 70)
Trial: 9166816
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (250 ml)
Trial: 3898904
Drug: Oral hyposensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hyposensitization with timothy whole pollen (4,315,000 PNU preseasonally and 8,915,000 PNU total for 6 months)
Trial: 29786336
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 2.5-3.0 mL human umbilical cord MSCs suspension containing (2-3)×10^7 cells, once a month for 2 times
Trial: 29786336
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate by intra-articular injection, once a week for 5 times
Trial: 22471128
Drug: Prednisone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (10 mg orally, once daily for 2 courses)
Trial: 20921898
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon alfa 2a 180 mcg per week + weight-based ribavirin for 12 weeks, followed by full dose PEG for 72 weeks
Trial: 10575171
Drug: Intramuscular preexposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular preexposure vaccination
Trial: 10575171
Drug: Intradermal preexposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal preexposure vaccination (0.1 mL dose)
Trial: 8793607
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole and 100 mg diclofenac
Trial: 1928632
Drug: Diazepam (DZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (DZ; 4‐28 mg)
Trial: 1928632
Drug: Subjective drug
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective drug effects
Trial: 7047258
Drug: Carbamazepine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (600 mg daily)
Trial: 23821759
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to oxaliplatin-based standard adjuvant chemotherapy regimen
Trial: 23821759
Drug: Standard adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant chemotherapy regimen without bevacizumab
Trial: 18829069
Drug: Contraceptive patch
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive patch (20 microg ethinylestradiol + 150 microg norelgestromin daily)
Trial: 18829069
Drug: Vaginal ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal ring (15 microg ethinylestradiol + 120 microg etonogestrel daily)
Trial: 18829069
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (30 microg ethinylestradiol + 150 microg levonorgestrel daily)
Trial: 14712334
Drug: Flumazenil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (2 mg bolus injection)
Trial: 11549528
Drug: Oral prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone, 20 mg/d for 2 weeks
Trial: 9802142
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg/d + Warfarin
Trial: 9802142
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg/d (2 h after intake)
Trial: 9802142
Drug: Aspirin (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (14 patients identified as secondary aspirin non-responders)
Trial: 9802142
Drug: Aspirin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (2 patients identified as primary aspirin non-responders)
Trial: 26775599
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist intervention focusing on medication compliance, smoking cessation, exercise, inhaler use, and follow-up.
Trial: 22641932
Drug: Direct contact
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct contact person-to-person prayer intervention (six weekly 1-hour sessions)
Trial: 20394720
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human interferon alpha-2b nasal spray
Trial: 11719835
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg single infusion)
Trial: 9386675
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered at 3 days of age (n = 25)
Trial: 9386675
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered at 1 month of age (n = 25)
Trial: 7898093
Drug: Beta-blockers and
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers and centrally acting drugs
Trial: 16757759
Drug: rhBMP-2 (1.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP-2 (1.50 mg/mL)
Trial: 15251269
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous alcohol infusion
Trial: 7828202
Drug: Treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated group (29 patients) - splint therapy, physical therapy, counseling, NSAID medications
Trial: 3352467
Drug: A mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mixture containing a fixed proportion of seven essential amino acids (L‐isoleucine 11.5%, L‐leucine 18.0%, L‐lysine 13.1%, L‐methionine 18.0%, L‐phenylalanine 18.0%, L‐threonine 8.2%, L‐valine 13.1%)
Trial: 28777195
Drug: Adjustment for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustment for Sequential Organ Failure Assessment score
Trial: 22211209
Drug: Enhanced mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced mental health intervention (family-based cognitive-behavioral therapy session + care linkage telephone contacts)
Trial: 19147485
Drug: Pharmacological cardioversion
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological cardioversion with anti-arrhythmic drugs for 4 weeks
Trial: 19147485
Drug: MMP-2 >767.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP-2 >767.0 ng/mL
Trial: 11403809
Drug: Antibiotics (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (clarithromycin 500 mg and amoxicillin 1000 mg twice daily) for 10 days
Trial: 9137510
Drug: Vinorelbine (VNB)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VNB) weekly IV bolus of 30 mg/m (14 patients)
Trial: 9137510
Drug: Vinorelbine (VNB)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VNB) continuous infusion (CI) schedule of 8 mg IV bolus on day 1 followed by 8 mg/m2/die CI day 1 to 4, q 21 days (16 patients)
Trial: 3501162
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (AP; dipyridamole 400 mg + aspirin 50 mg/day)
Trial: 20461319
Drug: Subantimicrobial dose
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subantimicrobial dose doxycycline (SDD) 20‐mg capsules twice a day
Trial: 17593515
Drug: steroid/Aza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid/Aza
Trial: 17593515
Drug: steroid/CsA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid/CsA
Trial: 12173200
Drug: Droperidol 0.625
RxNorm normalized name: droPERidol 0.625 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.625 mg i.v.
Trial: 10441094
Drug: Lepirudin treatment
RxNorm normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lepirudin treatment (0.4 mg/kg IV bolus, followed by 0.15 mg/kg/h intravenous infusion), n=65
Trial: 10441094
Drug: Lepirudin treatment
RxNorm normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lepirudin treatment in conjunction with thrombolysis (0.2 mg/kg, followed by 0.10 mg/kg/h), n=4
Trial: 10441094
Drug: Lepirudin prophylaxis
RxNorm normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lepirudin prophylaxis (0.10 mg/kg/h), n=43
Trial: 8588062
Drug: Serotonin reuptake
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin reuptake inhibitors over an 8-week period
Trial: 2222943
Drug: Intravenous captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous captopril (1 to 10 mg delivered at 10 min intervals over 50 to 80 min)
Trial: 2222943
Drug: Intravenous captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous captopril (incremental doses up to 40 mg)
Trial: 2222943
Drug: Intravenous captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous captopril with hydrochlorothiazide
Trial: 31755967
Drug: Intravitreal Ziv-Aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Ziv-Aflibercept 1.25 mg
Trial: 31755967
Drug: Intravitreal Ziv-Aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Ziv-Aflibercept 2.5 mg
Trial: 27918764
Drug: mFOLFOX6 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 plus onartuzumab (10 mg/kg)
Trial: 27465372
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g fiber from SCF/d
Trial: 27465372
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g fiber from SCF/d
Trial: 24586534
Drug: Daily vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vaginal gel and oral tablet regimens (PrEP)
Trial: 23096142
Drug: Stimulation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation therapy with drifting sinus gratings (n=8), performed 5 times a week over 4 weeks, 2×20 min sessions, combined with computer games
Trial: 10398312
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate (50 to 75 mg of elemental zinc orally daily) for 3 years after 1 year observation in Gr A.
Trial: 10398312
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 1 year followed by zinc supplementation (50 to 75 mg of elemental zinc orally daily) for 2 years in Gr B.
Trial: 8523654
Drug: PGE1 (0.02‐0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE1 (0.02‐0.05 micrograms.kg‐1.min‐1 administered intravenously throughout the operation)
Trial: 2578610
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (full supportive treatment only)
Trial: 30739747
Drug: MISTIE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MISTIE treatment (1·0 mg alteplase every 8 h for up to nine doses)
Trial: 30739747
Drug: MISTIE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MISTIE treatment
Trial: 26085198
Drug: Intelligence seven
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intelligence seven needle therapy
Trial: 21414953
Drug: Baclofen 20
RxNorm normalized name: baclofen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 20 mg t.i.d.
Trial: 14709454
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron intravenously (high-risk group)
Trial: 14709454
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with ondansetron (both groups)
Trial: 2252164
Drug: High potency
RxNorm normalized name: High Potency B+C
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High potency (HP) extract (9-dose regimen)
Trial: 6118758
Drug: dl‐propranolol (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl‐propranolol (640 mg/day)
Trial: 6118758
Drug: d‐propranolol (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐propranolol (640 mg/day)
Trial: 20652630
Drug: Two-session HIV/HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-session HIV/HCV counseling and education (C&E) model added to treatment as usual (TAU)
Trial: 20652630
Drug: One-session therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session therapeutic alliance (TA) intervention conducted by outpatient counselors to facilitate treatment entry plus TAU
Trial: 19649583
Drug: 1,5-pentanediol (PD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,5-pentanediol (PD) gel
Trial: 11167372
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (200 microg, twice daily)
Trial: 9771300
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of 0.125% bupivacaine 12.5 mg h‐1 and morphine 0.25 mg h‐1 (EXI group)
Trial: 9771300
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with intravenous morphine (1 mg bolus, 5‐min lock‐out and maximum dose 20 mg 4h‐1)
Trial: 2246759
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine added to metoclopramide regimen
Trial: 44671
Drug: Ordinary metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary metoprolol tablets 0.1 g b.i.d.
Trial: 44671
Drug: Metoprolol slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol slow-release tablets (Durules) 0.2 g once daily
Trial: 44671
Drug: Metoprolol slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol slow-release tablets (Durules)
Trial: 44671
Drug: Ordinary metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary metoprolol tablets